ATE408699T1 - Verabreichung von nukleinsäuren und proteinen an zellen - Google Patents

Verabreichung von nukleinsäuren und proteinen an zellen

Info

Publication number
ATE408699T1
ATE408699T1 AT00909483T AT00909483T ATE408699T1 AT E408699 T1 ATE408699 T1 AT E408699T1 AT 00909483 T AT00909483 T AT 00909483T AT 00909483 T AT00909483 T AT 00909483T AT E408699 T1 ATE408699 T1 AT E408699T1
Authority
AT
Austria
Prior art keywords
proteins
cells
nucleic acids
administration
polynucleotides
Prior art date
Application number
AT00909483T
Other languages
English (en)
Inventor
Peter Francis Joseph O'hare
Nadia Michelle Normand
Original Assignee
Phogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9905444.7A external-priority patent/GB9905444D0/en
Priority claimed from GBGB9930499.0A external-priority patent/GB9930499D0/en
Application filed by Phogen Ltd filed Critical Phogen Ltd
Application granted granted Critical
Publication of ATE408699T1 publication Critical patent/ATE408699T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
AT00909483T 1999-03-10 2000-03-10 Verabreichung von nukleinsäuren und proteinen an zellen ATE408699T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9905444.7A GB9905444D0 (en) 1999-03-10 1999-03-10 Delivery of sustances to cells
GBGB9930499.0A GB9930499D0 (en) 1999-12-24 1999-12-24 Delivery of substances to cells

Publications (1)

Publication Number Publication Date
ATE408699T1 true ATE408699T1 (de) 2008-10-15

Family

ID=26315249

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00909483T ATE408699T1 (de) 1999-03-10 2000-03-10 Verabreichung von nukleinsäuren und proteinen an zellen

Country Status (9)

Country Link
US (1) US20040171044A1 (de)
EP (1) EP1159441B8 (de)
JP (1) JP2002537828A (de)
AT (1) ATE408699T1 (de)
AU (1) AU767195B2 (de)
CA (1) CA2365625A1 (de)
DE (1) DE60040274D1 (de)
MX (1) MXPA01009073A (de)
WO (1) WO2000053722A2 (de)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
GB0022101D0 (en) * 2000-09-08 2000-10-25 Phogen Ltd Delivery of substances to cells
US7223600B2 (en) 2000-11-29 2007-05-29 The Norwegian Radium Hospital Research Foundation Photochemical internalization for delivery of molecules into the cytosol
PT1339862E (pt) 2000-11-29 2014-02-17 Pci Biotech As Internalização fotoquímica para entrega de molécula no ciosol mediada por vírus
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
EP1432724A4 (de) 2002-02-20 2006-02-01 Sirna Therapeutics Inc Durch rna-interferenz vermittelte inhibierung von map-kinase-genen
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1660524B1 (de) 2003-08-15 2011-01-12 University of Florida Research Foundation, Inc. Die identifikation von polynukleotiden von porphyromonas gingivalis-virulenz zur diagnose, behandlung und beobachtung von periodontalerkrankungen
GB0321311D0 (en) * 2003-09-12 2003-10-15 Phogen Ltd Delivery of substances to cells
CN102989009B (zh) 2003-12-31 2015-06-03 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
EP1720568A2 (de) * 2004-02-19 2006-11-15 Coley Pharmaceutical Group, Inc. Immunstimulatorische virale rna-oligonucleotide
AU2005222902B2 (en) 2004-03-12 2010-06-10 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
ATE501252T1 (de) 2004-06-22 2011-03-15 Univ Illinois Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
WO2007002718A2 (en) 2005-06-27 2007-01-04 Alnylam Pharmaceuticals, Inc. Rnai modulation of hif-1 and theraputic uses thereof
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2009051846A2 (en) 2007-10-18 2009-04-23 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
JP5554925B2 (ja) 2006-01-20 2014-07-23 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト非小細胞肺癌における転座及び変異体ｒｏｓキナーゼ
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
WO2007109097A2 (en) 2006-03-16 2007-09-27 Alnylam Pharmaceuticals, Inc. RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
NZ571568A (en) 2006-03-31 2010-11-26 Alnylam Pharmaceuticals Inc Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
EP2447360A1 (de) 2006-04-14 2012-05-02 Cell Signaling Technology, Inc. Gendefekte und Mutante ALK-Kinase in festen menschlichen Tumoren
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP2049658A2 (de) 2006-07-21 2009-04-22 Silence Therapeutics AG Mittel zur hemmung der expression von proteinkinase 3
JPWO2008015841A1 (ja) * 2006-08-02 2009-12-17 梅澤　喜夫 キナーゼ阻害性融合タンパク質と医薬組成物
WO2008030986A2 (en) 2006-09-06 2008-03-13 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
JP5596980B2 (ja) 2007-02-28 2014-10-01 アメリカ合衆国 ブラキュリポリペプチドおよび使用方法
HUE040417T2 (hu) 2007-05-04 2019-03-28 Marina Biotech Inc Aminosavlipidek és alkalmazásuk
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
ES2477271T3 (es) 2007-08-13 2014-07-16 Baxter International Inc. Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson
CA2703165A1 (en) 2007-10-22 2009-04-30 The Regents Of The University Of California Biomarkers for prenatal diagnosis of congenital cytomegalovirus
ES2489840T3 (es) 2008-03-05 2014-09-02 The Regents Of The University Of California Pronóstico molecular y clasificación de melanoma maligno en base a marcadores seleccionados entre la lista que consiste en RGS1, NCOA3, SPP1, PHIP
EP2276511A2 (de) * 2008-04-15 2011-01-26 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Zusammensetzungen und verfahren zur abgabe von hemmenden oligonucleotiden
US10485879B2 (en) 2008-04-15 2019-11-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
EP2291544B1 (de) 2008-05-16 2017-10-25 The Children's Hospital of Philadelphia Genetische veränderungen auf chromosomen 21q, 6q und 15q sowie verfahren zur verwendung davon bei der diagnose und behandlung von typ-i-diabetes
ATE550024T1 (de) 2008-05-30 2012-04-15 Univ Yale Gezielte oligonucleotid-zusammensetzungen zur modifizierung der genexpression
EP2297322A1 (de) 2008-06-04 2011-03-23 The Board of Regents of The University of Texas System Modulation der genexpression über das abzielen kleiner endogener rna auf genpromotoren
EP2165710A1 (de) 2008-09-19 2010-03-24 Institut Curie Tyrosinkinaserezeptor Tyro3 als therapeutisches Target bei der Behandlung eines Blasentumors
CN104382853A (zh) 2008-10-16 2015-03-04 玛瑞纳生物技术有限公司 基因沉默治疗剂的脂质体有效递送方法和组合物
US9587249B2 (en) 2008-10-27 2017-03-07 Baxalta GmbH Models of thrombotic thrombocytopenic purpura and methods of use thereof
EP2198879A1 (de) 2008-12-11 2010-06-23 Institut Curie CD74-modulierender Wirkstoff zur Regulierung der Dendritenzellmigration und Verfahren zur Untersuchung der Bewegungsfähigkeit einer Zelle
US9364477B2 (en) 2009-02-12 2016-06-14 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
WO2010091878A2 (en) 2009-02-13 2010-08-19 Silence Therapeutics Ag Means for inhibiting the expression of opa1
JP2012517815A (ja) 2009-02-18 2012-08-09 サイレンス・セラピューティクス・アーゲー Ａｎｇ２の発現を阻害するための手段
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2010226604A1 (en) 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408916A2 (de) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von ctgf (connective tissue growth factor) unter verwendung von sina (short interfering nucleic acid)
JP2012521765A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた細胞内接着分子１（ＩＣＡＭ−１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2411516A1 (de) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna-interferenz-vermittelte hemmung der genexpression von ask1 (apoptose-signalregulierende kinase 1) unter verwendung von sina (short interfering nucleic acid)
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012521763A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子１（ＳＴＡＴ１）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012521762A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた神経成長因子β鎖（ＮＧＦβ）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012523225A (ja) 2009-04-10 2012-10-04 アソシアシオン・アンスティテュ・ドゥ・ミオロジー 疾患の処置のためのトリシクロ−ｄｎａアンチセンスオリゴヌクレオチド、組成物及び方法
EP2421972A2 (de) 2009-04-24 2012-02-29 The Board of Regents of The University of Texas System Modulation der genexpression mit auf genregionen nach 3-untranslatierten regionen gerichteten oligomeren
EP2266550A1 (de) 2009-06-15 2010-12-29 Institut Curie Antagonisten von ß-Catenin zur Prävention und/oder Behandlung neurodegenerativer Erkrankungen
TWI465238B (zh) 2009-12-09 2014-12-21 Nitto Denko Corp Ｈｓｐ４７表現之調節
CN108404123A (zh) 2010-01-15 2018-08-17 康奈尔大学 降低细胞内蛋白质水平的方法
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139842A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
CA2800065A1 (en) 2010-05-21 2011-11-24 Peptimed, Inc. Reagents and methods for treating cancer
US20130149320A1 (en) 2010-05-31 2013-06-13 Centre National De La Recherche Scientifique Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer
CA2801928C (en) 2010-06-24 2018-04-10 Quark Pharmaceuticals, Inc. Double stranded rna compounds to rhoa and use thereof
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
US20130210663A1 (en) 2010-08-04 2013-08-15 Cizzle Biotechnology Limited Methods and compounds for the diagnosis and treatment of cancer
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP3372684B1 (de) 2010-08-24 2020-10-07 Sirna Therapeutics, Inc. Einsträngige rnai-mittel mit einem internen nukleinsäurefreien spacer
EP2609106A4 (de) 2010-08-26 2014-03-19 Merck Sharp & Dohme Durch rna-interferenz vermittelte inhibition der prolyl-hydroxylase-domäne-2 (phd2)-genexpression unter verwendung von short-interfering-nukleinsäuren (sina)
WO2012047631A2 (en) 2010-09-27 2012-04-12 The Children's Hospital Of Philadelphia Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
WO2012044979A2 (en) 2010-10-01 2012-04-05 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Manipulation of stem cell function by p53 isoforms
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
AU2011323508B2 (en) 2010-11-01 2017-04-27 Peptimed, Inc. Compositions of a peptide targeting system for treating cancer
EP2455456A1 (de) 2010-11-22 2012-05-23 Institut Curie Verwendung von Kinesininhibitoren bei der Behandlung von HIV-Infektion und Verfahren zu deren Abtastung
JP2014510721A (ja) 2011-02-15 2014-05-01 イミューン デザイン コーポレイション ベクターワクチンによる免疫原特異的免疫応答を強化するための方法
EP2681314B1 (de) 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von lungenerkrankungen und läsionen
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2012175481A1 (en) 2011-06-20 2012-12-27 Institut Curie Compositions and methods for treating leukemia
EP2557089A2 (de) 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Zusammensetzungen und Verfahren zur Immunmodulation
DK2581448T3 (en) 2011-10-13 2015-04-27 Ass Inst De Myologie Tricyclo-DNA phosphorothioate
BR112014011417B1 (pt) 2011-11-11 2021-10-13 Fred Hutchinson Cancer Research Center Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
CA2858630A1 (en) 2012-01-12 2013-07-18 Quark Pharmaceuticals, Inc. Combination therapy for treating hearing and balance disorders
EP2617434A1 (de) 2012-01-20 2013-07-24 Laboratorios Del. Dr. Esteve, S.A. HIV-1-Integrase-defiziente Immunogene und Verfahren zum Beladen von dentritischen Zellen mit besagten Immunogenen
WO2013123996A1 (en) 2012-02-24 2013-08-29 Astrazeneca Uk Limited Novel sirna inhibitors of human icam-1
DK2838998T3 (en) 2012-04-18 2018-01-15 Cell Signaling Technology Inc EGFR AND ROS1 IN CANCER
BR112015004747A2 (pt) 2012-09-12 2017-11-21 Quark Pharmaceuticals Inc moléculas oligonucleotídicas de fita dupla para p53 e métodos de uso das mesmas
DK2895608T3 (en) 2012-09-12 2019-01-21 Quark Pharmaceuticals Inc DOUBLE-STRENGTHED OIGONUCLEOTIDE MOLECULES FOR P53 AND PROCEDURES FOR USING IT
AU2014223432A1 (en) 2013-02-28 2015-09-03 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat EPAS1-related diseases
WO2014135655A1 (en) 2013-03-06 2014-09-12 Institut Curie Compositions and methods for treating muscle-invasive bladder cancer
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
WO2014154898A1 (en) 2013-03-29 2014-10-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Prognosis and treatment of cancers
WO2015020960A1 (en) 2013-08-09 2015-02-12 Novartis Ag Novel lncrna polynucleotides
EP2853595A1 (de) 2013-09-30 2015-04-01 Soluventis GmbH NOTCH 1-spezifische siRNA-Moleküle
EP3542816A1 (de) 2014-02-14 2019-09-25 Immune Design Corp. Immuntherapie von krebs durch kombination von lokaler und systemischer immunstimulation
CN106459076B (zh) 2014-05-13 2019-01-04 诺华股份有限公司 用于诱导软骨发生的化合物和组合物
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
EP3186378A1 (de) 2014-08-27 2017-07-05 Peptimed, Inc. Anti-tumor-zusammensetzungen und -verfahren
WO2016083624A1 (en) 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Means for inhibiting the expression of edn1
CN108064313B (zh) 2015-03-17 2021-07-30 箭头药业股份有限公司 用于抑制因子xii的基因表达的组合物和方法
MX2017014641A (es) 2015-05-29 2018-01-23 Arrowhead Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
WO2016196366A1 (en) 2015-05-29 2016-12-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extension of replicative lifespan in diseases of premature aging using p53 isoforms
AU2016306275A1 (en) 2015-08-07 2018-02-08 Arrowhead Pharmaceuticals, Inc. RNAi therapy for Hepatitis B virus infection
JOP20210043A1 (ar) 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
EP3156497A1 (de) 2015-10-16 2017-04-19 Centre National de la Recherche Scientifique (C.N.R.S.) Trpv2 als biomarker und als therapeutisches target für melanome
WO2017184586A1 (en) 2016-04-18 2017-10-26 The Trustees Of Columbia University In The City Of New York Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
KR102426487B1 (ko) 2016-06-06 2022-07-27 애로우헤드 파마슈티컬스 인코포레이티드 5'-시클로-포스포네이트 변형된 뉴클레오티드
EP3269734A1 (de) 2016-07-15 2018-01-17 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Verfahren und zusammensetzungen zur behandlung von krebs
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
BR112019014282A2 (pt) 2017-01-10 2020-03-03 Arrowhead Pharmaceuticals, Inc. Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso
EP3649240A4 (de) 2017-07-06 2021-07-07 Arrowhead Pharmaceuticals, Inc. Rnai-agenten zur hemmung der expression von alpha-enac und verwendungsverfahren
EP3449978A1 (de) 2017-09-01 2019-03-06 Universite Paris Descartes Inhibitoren des arylkohlenwasserstoffrezeptors zur behandlung von weichteilsarkom und prävention von neurofibromwachstum und/oder transformation auf malignen peripheren nervenscheidentumoren
CN111107853A (zh) 2017-09-11 2020-05-05 箭头药业股份有限公司 用于抑制载脂蛋白C-III (APOC3)的表达的RNAi试剂和组合物
JP7281452B2 (ja) 2017-09-14 2023-05-25 アローヘッド ファーマシューティカルズ インコーポレイテッド アンジオポエチン様３（ＡＮＧＰＴＬ３）の発現を阻害するためのＲＮＡｉ剤および組成物、ならびに使用方法
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
CA3079413A1 (en) 2017-10-17 2019-04-25 Arrowhead Pharmaceuticals, Inc. Rnai agents and compositions for inhibiting expression of asialoglycoprotein receptor 1
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
CA3129261A1 (en) 2019-02-07 2020-08-13 Arrowhead Pharmaceuticals, Inc. Rnai agents for hepatitis b virus infection
CA3133155A1 (en) 2019-03-19 2020-09-24 Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron Combination therapy for the treatment for cancer
TW202106294A (zh) 2019-04-18 2021-02-16 美商健生醫藥公司 用於治療ｂ型肝炎病毒感染的組合療法（一）
CN114072142A (zh) 2019-04-18 2022-02-18 杨森制药公司 用于治疗乙型肝炎病毒感染的组合疗法
EP3986456A1 (de) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Kombination von hepatitis-b-virus(hbv)-impfstoffen und auf hbv abzielender rnai
JP2022536945A (ja) 2019-06-18 2022-08-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ
EP3808763A1 (de) 2019-10-17 2021-04-21 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Verbindungen zur immunmodulation
EP4114944A1 (de) 2020-03-04 2023-01-11 Ninovax Produkte zur unterdrückung oder verringerung der expression oder aktivität einer snorna und verwendungen davon bei der behandlung von krebs
TW202146011A (zh) 2020-03-05 2021-12-16 美商詹森藥物公司 治療b型肝炎病毒感染之組合療法
AU2021242321A1 (en) 2020-03-26 2022-10-06 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use
TW202207950A (zh) 2020-06-22 2022-03-01 美商詹森藥物公司 治療d型肝炎病毒感染之組合物及方法
CA3189065A1 (en) 2020-09-11 2022-03-17 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
AU2021340710A1 (en) 2020-09-11 2023-04-06 Arrowhead Pharmaceuticals, Inc. Skeletal muscle delivery platforms and methods of use
IL301185A (en) 2020-09-11 2023-05-01 Arrowhead Pharmaceuticals Inc Lipid conjugates for the transport of medicinal substances
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
US11549112B1 (en) 2021-06-21 2023-01-10 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
WO2023281434A1 (en) 2021-07-09 2023-01-12 Janssen Pharmaceuticals, Inc. Use of oligonucleotides for individuals with renal impairment
US20230277600A1 (en) 2021-10-20 2023-09-07 University Of Rochester Treatment Of Age-Related White Matter Loss By Competitive Replacement Of Glial Cells
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
US11912997B2 (en) 2022-06-15 2024-02-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935777A (en) * 1991-02-19 1999-08-10 University Of Florida Research Foundation, Inc. Entomopoxvirus expression system
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
EP0845043B1 (de) * 1995-07-28 2007-06-27 Marie Curie Cancer Care Transportproteine und deren verwendungen
JP2001519647A (ja) * 1995-12-28 2001-10-23 カイロン コーポレイション 標的細胞中へのウイルスおよび粒子の取り込みおよびインターナリゼーションのためのレセプター特異的キメラウイルス表面ポリペプチド
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US6034135A (en) * 1997-03-06 2000-03-07 Promega Biosciences, Inc. Dimeric cationic lipids
GB9705903D0 (en) * 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
DE69827260T2 (de) * 1997-07-24 2006-02-16 PerSeptive Biosystems, Inc., Framingham Konjugate von transportpeptiden und nukleinsäureanaloga und deren verwendung
GB9816761D0 (en) * 1998-07-31 1998-09-30 Phogen Limited Herpesvirus preparations and their uses
GB9930519D0 (en) * 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins

Also Published As

Publication number Publication date
US20040171044A1 (en) 2004-09-02
AU3176500A (en) 2000-09-28
CA2365625A1 (en) 2000-09-14
EP1159441B8 (de) 2008-10-29
MXPA01009073A (es) 2002-05-06
DE60040274D1 (de) 2008-10-30
EP1159441A2 (de) 2001-12-05
WO2000053722A3 (en) 2001-07-12
AU767195B2 (en) 2003-11-06
JP2002537828A (ja) 2002-11-12
EP1159441B1 (de) 2008-09-17
WO2000053722A2 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
ATE408699T1 (de) Verabreichung von nukleinsäuren und proteinen an zellen
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
DE69532532T8 (de) Chimerische papillomavirus-ahnliche partikel
AR020048A1 (es) Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero.
DE50006269D1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
DE69637147D1 (de) Transportproteine und deren verwendungen
DE69730218D1 (de) Fusogene liposomen
ATE184052T1 (de) Gdf-1 und uog1 proteine
WO2003065003A3 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
TR200103339T2 (tr) Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
ES2114548T3 (es) Procedimiento y composiciones para ensayos de complementacion de enzima utilizando la region omega de beta-galactosidasa.
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
ES2157900T3 (es) Nuevos conjugados de proteinas y policationes.
TR199902575T2 (xx) Peptitler, proteinler ve nükleik asitler için stabil farmasötik uygulama formu.
WO2004067555A3 (en) Protein and peptide delivery to mammalian cells in vitro
TR199802376T1 (xx) Aspergıllus Phoenıces'den Oksalat Dekarboksilaz Kodlayan Gen.
WO2001042277A3 (en) Complementary peptide ligands generated from the human genome
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
ATE355302T1 (de) N-substituierte d-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
AU590861B2 (en) New human lymphotoxin (TNF-beta) polypeptides their prepartion and use
ATE414771T1 (de) Galaninrezeptor, nukleinsäuren,transformierte zellen und verwendungen
WO2003002598A3 (en) Peptides for use as translocation factors
DE69831242D1 (de) Erhöhte herstellung von sekretierten proteinen durch rekombinante hefezellen
DE69631624D1 (de) Antikörper gegen menschliches restrictin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee